PFS2 is a novel endpoint recommended by the European Medicines Agency (EMA) for assessing outcomes of sequential therapies.1
MEDIAN PFS2†2
During the SPARTAN study, ERLEADA® + ADT offered a longer PFS2 vs placebo + ADT, delaying the time from randomisation to disease progression during first subsequent treatment after progression to mCRPC, or death from any cause.2
REFERENCES :
1- Small EJ, et al. Poster 144 presented at ASCO genitourinary cancers symposium, CA, USA, 2019.
2- Smith MR, et al. N Engl J Med. 2018;378:1408–18.
1- Small EJ, et al. Poster 144 presented at ASCO genitourinary cancers symposium, CA, USA, 2019.
2- Smith MR, et al. N Engl J Med. 2018;378:1408–18.
CP-142079
